This list is an analysis based on recent market events. It's not an investment recommendation.
About
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
The current price of BDLSF is $0.22 USD — it has increased by +0% in the past 24 hours. Watch Inoviq stock price performance more closely on the chart.
What is Inoviq stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Inoviq stocks are traded under the ticker BDLSF.
What is Inoviq market cap?▼
Today Inoviq has the market capitalization of 30.69M
When is the next Inoviq earnings date?▼
Inoviq is going to release the next earnings report on February 19, 2027.
What is Inoviq revenue for the last year?▼
Inoviq revenue for the last year amounts to 351,645.61 USD.
What is Inoviq net income for the last year?▼
BDLSF net income for the last year is -4.42M USD.
How many employees does Inoviq have?▼
As of September 07, 2026, the company has 15 employees.